Overview

Pharmacokinetic (PK) Bioequivalence and Pharmacodynamics (PD) of Julphar Insulin N and Huminsulin® Basal

Status:
Completed
Trial end date:
2017-01-20
Target enrollment:
Participant gender:
Summary
This study in healthy volunteers aims to demonstrate similar PK and PD properties of the new human isophane Insulin, Julphar Insulin N, and the already approved reference Insulin, Huminsulin® Basal. All participants will receive both study treatments on two separate dosing days.
Phase:
Phase 1
Details
Lead Sponsor:
Julphar Gulf Pharmaceutical Industries
Collaborator:
Profil Institut für Stoffwechselforschung GmbH
Treatments:
Insulin
Insulin, Globin Zinc
Insulin, Isophane
Isophane insulin, beef
Isophane Insulin, Human